Agustin MD - Allovir Advisor

ALVRDelisted Stock  USD 9.81  0.15  1.55%   

Insider

Agustin MD is Advisor of Allovir
Age 60
Phone617 433 2605
Webhttps://www.allovir.com

Allovir Management Efficiency

The company has return on total asset (ROA) of (0.3653) % which means that it has lost $0.3653 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8033) %, meaning that it created substantial loss on money invested by shareholders. Allovir's management efficiency ratios could be used to measure how well Allovir manages its routine affairs as well as how well it operates its assets and liabilities.
Allovir currently holds 5.24 M in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Allovir has a current ratio of 8.02, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Allovir's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Hennie HoogenboomMerus BV
N/A
Joseph ZakrzewskiAN2 Therapeutics
63
Elizabeth BuckBlack Diamond Therapeutics
50
Joan WoodStoke Therapeutics
N/A
Chris MBACrinetics Pharmaceuticals
N/A
MSc MBAAnaptysBio
48
Jennifer MichaelsonCullinan Oncology LLC
57
Hunter MDAerovate Therapeutics
59
Dennis MulroyAnaptysBio
70
Jacquelyn JDCullinan Oncology LLC
47
Eric EasomAN2 Therapeutics
57
TaiAn LinBlack Diamond Therapeutics
N/A
JD Esq4D Molecular Therapeutics
73
Jillian ConnellMerus BV
N/A
MBA BSAN2 Therapeutics
49
Richa PoddarAgios Pharm
42
Timothy PigotAerovate Therapeutics
53
Michael AlleyAN2 Therapeutics
N/A
Josh EizenAN2 Therapeutics
N/A
Fangyong DuAdagene
54
Richard MDLyell Immunopharma
73
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Allovir operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people. Allovir (ALVR) is traded on NASDAQ Exchange in USA. It is located in 1100 Winter Street, Waltham, MA, United States, 02451 and employs 6 people. Allovir is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Allovir Leadership Team

Elected by the shareholders, the Allovir's board of directors comprises two types of representatives: Allovir inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allovir. The board's role is to monitor Allovir's management team and ensure that shareholders' interests are well served. Allovir's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allovir's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sonia Choi, Senior Relations
Agustin MD, Advisor
Dana MBA, VP Operations
Ann Leen, Chief Officer
Cintia PharmD, Chief Officer
David Hallal, Executive Board
Jeroen Beek, Consultant
Diana MD, CEO Director
Ugo Perlingieri, Head Operations
Brett Hagen, Chief Officer
Edward JD, General Secretary
Dana Alexander, Senior Operations

Allovir Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allovir a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Allovir

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allovir position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allovir will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Allovir could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allovir when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allovir - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allovir to buy it.
The correlation of Allovir is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allovir moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allovir moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allovir can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allovir. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Other Consideration for investing in Allovir Stock

If you are still planning to invest in Allovir check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allovir's history and understand the potential risks before investing.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Bonds Directory
Find actively traded corporate debentures issued by US companies
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges